Genetic association studies in drug-induced liver injury

Drug Metabolism Reviews

Volumn 44, Issue 1, 2012, Pages 116-126

  Daly, Ann K ^a   Day, Christopher P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

cytochrome P450; genome wide association study; HLA; NAT2

Indexed keywords

AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; DICLOFENAC; FLUCLOXACILLIN; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR2 ANTIGEN; HLA DR6 ANTIGEN; HLA DRB1 ANTIGEN; ISONIAZID; LUMIRACOXIB; NEVIRAPINE; PAZOPANIB; TICLOPIDINE; TOLCAPONE; VALPROIC ACID; XIMELAGATRAN;

AEROBIC METABOLISM; ALLELE; AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; DNA POLYMORPHISM; DRUG DISPOSITION; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HLA SYSTEM; HUMAN; INNATE IMMUNITY; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TOXIC HEPATITIS;

ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; DRUG-INDUCED LIVER INJURY; GENES, MHC CLASS I; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HLA ANTIGENS; HUMANS; IMMUNITY, INNATE; ISONIAZID; OXIDATIVE STRESS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 84855908033     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2011.605790     Document Type: Review

References (86)

1. Acuna, G., Foernzler, D., Leong, D., Rabbia, M., Smit, R., Dorflinger, E., et al. (2002). Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J 2:327-334. (Pubitemid 35439475)
2. Adam, J., Pichler, W. J., Yerly, D. (2011). Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 71:701-707.
3. Aithal, G. P., Day, C. P., Leathart, J. B. S., Daly, A. K. (2000). Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenacinduced hepatitis. Pharmacogenetics 10:511-518.
4. Aithal, G. P., Ramsay, L., Daly, A. K., Sonchit, N., Leathart, J. B., Alexander, G., et al. (2004). Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430-1440. (Pubitemid 38569066)
5. Aithal, G. P., Rawlins, M. D., Day, C. P. (1999). Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J 319:1541-1541.
6. Andrade, R. J., Lucena, M. I., Alonso, A., Garcia-Cortes, M., Garcia-Ruiz, E., Benitez, R., et al. (2004). HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39:1603-1612. (Pubitemid 38702661)
7. Andrews, E., Armstrong, M., Tugwood, J., Swan, D., Glaves, P., Pirmohamed, M., et al. (2010). A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 51:1656-1664.
8. Becquemont, L. (2010). HLA: a pharmacogenomics success story. Pharmacogenomics 11:277-281.
9. Berson, A., Freneaux, E., Larrey, D., Lepage, V., Douay, C., Mallet, C., et al. (1994). Possible role of HLA in hepatotoxicity-an exploratory-study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 20:336-342. (Pubitemid 24082501)
10. Bhatnagar, P., Day, C. P., Aithal, G., Pirmohamed, M., Bernal, W., Daly, A. K. (2008). Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. Toxicology 253:10.
11. Bjornsson, E. (2009). The natural history of drug-induced liver injury. Semin Liver Dis 29:357-363.
12. Bourdi, M., Eiras, D. P., Holt, M. P., Webster, M. R., Reilly, T. P., Welch, K. D., et al. (2007). Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminopheninduced liver injury. Chem Res Toxicol 20:208-216. (Pubitemid 46408857)
13. Bourdi, M., Masubuchi, Y., Reilly, T. P., Amouzadeh, H. R., Martin, J. L., George, J. W., et al. (2002). Protection against acetaminopheninduced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 35:289-298. (Pubitemid 34106367)
14. Bozok Cetintas, V., Erer, O. F., Kosova, B., Ozdemir, I., Topcuoglu, N., Aktogu, S., et al. (2008). Determining the relation between N-acetyltransferase- 2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks 56:81-86.
15. Carr, D. F., Alfirevic, A., Tugwood, J. D., Barratt, B. J., Sherwood, J., Smith, J., et al. (2007). Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet Genomics 17:961-972. (Pubitemid 350293796)
16. *1502 screening in Taiwan. N Engl J Med 364:1126-1133.
17. Cho, H. J., Koh, W. J., Ryu, Y. J., Ki, C. S., Nam, M. H., Kim, J. W., et al. (2007). Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 87:551-556.
18. Choi, J. H., Ahn, B. M., Yi, J., Lee, J. H., Nam, S. W., Chon, C. Y., et al. (2007). MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 17:403-415. (Pubitemid 46763385)
19. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., et al. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486.
20. Daly, A. K. (2004). Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 4:1733-1744. (Pubitemid 39654459)
21. Daly, A. K., Aithal, G. P., Leathart, J. B., Swainsbury, R. A., Dang, T. S., Day, C. P. (2007). Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272-281. (Pubitemid 46108755)
22. *5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41:816-819.
23. Deng, X., Stachlewitz, R. F., Liguori, M. J., Blomme, E. A., Waring, J. F., Luyendyk, J. P., et al. (2006). Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 319:1191-1199.
24. Dickinson, D. S., Bailey, W. C., Hirschowitz, B. I., Soong, S. J., Eidus, L., Hodgkin, M. M. (1981). Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 3:271-279. (Pubitemid 11053230)
25. Donaldson, P. T., Daly, A. K., Henderson, J., Graham, J., Pirmohamed, M., Bernal, W., et al. (2010). Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 53:1049-1053.
26. Durbin, R. M., Abecasis, G. R., Altshuler, D. L., Auton, A., Brooks, L. D., Durbin, R. M., et al. (2010). A map of human genome variation from population-scale sequencing. Nature 467:1061-1073.
27. Eichelbaum, M., Musch, E., Castroparra, M., Vonsassen, W. (1982). Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism. Br J Clin Pharmacol 14:P575-P576
28. Fontana, R. J., Seeff, L. B., Andrade, R. J., Bjornsson, E., Day, C. P., Serrano, J., et al. (2010). Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 52:730-742.
29. Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., et al. (2009). Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design, and conduct. Drug Saf 32:55-68.
30. Geier, A., Wagner, M., Dietrich, C. G., Trauner, M. (2007). Principles of hepatic organic anion transporter regulation during cholestasis, inflammation, and liver regeneration. Biochim Biophys Acta 1773:283-308. (Pubitemid 46275063)
31. Gronhagen-Riska, C., Hellstrom, P. E., Froseth, B. (1978). Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 118:461-466. (Pubitemid 9027187)
32. Grove, J., Daly, A. K., Bassendine, M. F., Day, C. P. (1997). Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26:143-146. (Pubitemid 27280318)
33. Grove, J., Daly, A. K., Bassendine, M. F., Gilvarry, E., Day, C. P. (2000). Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 46:540-545. (Pubitemid 30305820)
34. Haas, D. W., Bartlett, J. A., Andersen, J. W., Sanne, I., Wilkinson, G. R., Hinkle, J., et al. (2006). Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43:783-786. (Pubitemid 44330746)
35. Haenisch, S., Zimmermann, U., Dazert, E., Wruck, C. J., Dazert, P., Siegmund, W., et al. (2007). Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7:56-65. (Pubitemid 46322080)
36. Hautekeete, M. L., Horsmans, Y., Van Waeyenberge, C., Demanet, C., Henrion, J., Verbist, L., et al. (1999). HLA association of amoxicillin- clavulanate-induced hepatitis. Gastroenterology 117:1181-1186. (Pubitemid 29512678)
37. Hayashi, S., Watanabe, J., Kawagiri, K. (1991). Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 110:559-565.
38. Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., et al. (2008). Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 8:29-33.
39. Huang, Y. S., Chern, H. D., Su, W. J., Wu, J. C., Chang, S. C., Chiang, C. H., et al. (2003). Cytochrome p450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924-930.
40. Huang, Y. S., Chern, H. D., Su, W. J., Wu, J. C., Lai, S. L., Yang, S. Y., et al. (2002). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883-889.
41. Huang, Y. S., Su, W. J., Huang, Y. H., Chen, C. Y., Chang, F. Y., Lin, H. C., et al. (2007). Genetic polymorphisms of manganese superoxide dismutase, NAD (P) H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 47:128-134.
42. Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499. (Pubitemid 40861991)
43. Kato, S., Shields, P. G., Caporaso, N. E., Hoover, R. N., Trump, B. F., Sugimura, H., et al. (1992). Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 52:6712-6715.
44. Kim, S. H., Kim, S. H., Bahn, J. W., Kim, Y. K., Chang, Y. S., Shin, E. S., et al. (2009). Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10:1767-1779.
45. Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B., et al. (2008). Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8:186-195. (Pubitemid 351712643)
46. Kuhlenbaumer, G., Hullmann, J., Appenzellerm, S. (2011). Novel genomic techniques open new avenues in the analysis of monogenic disorders. Hum Mutat 32:144-151.
47. Lang, C., Meier, Y., Stieger, B., Beuers, U., Lang, T., Kerb, R., et al. (2007). Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 17:47-60. (Pubitemid 46183791)
48. Lee, S. W., Chung, L. S., Huang, H. H., Chuang, T. Y., Liou, Y. H., Wu, L. S. (2010). NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 14:622-626.
49. Leiro, V., Fernandez-Villar, A., Valverde, D., Constenla, L., Vazquez, R., Pineiro, L., et al. (2008). Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 28:835-839. (Pubitemid 351818646)
50. Lonjou, C., Thomas, L., Borot, N., Ledger, N., De Toma, C., Lelouet, H., et al. (2006). A marker for Stevens-Johnson syndrome...: ethnicity matters. Pharmacogenomics J 6:265-268. (Pubitemid 44137953)
51. Lucena, M. I., Andrade, R. J., Martinez, C., Ulzurrun, E., Garcia-Martin, E., Borraz, Y., et al. (2008). Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic druginduced liver injury. Hepatology 48:588-596.
52. Lucena, M. I., Garcia-Martin, E., Andrade, R. J., Martinez, C., Stephens, C., Ruiz, J. D., et al. (2010). Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 52:303-312.
53. Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., et al. (2011). Susceptibility to amoxicillin-clavulanateinduced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141:338-347.
54. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359:727-732. (Pubitemid 34215071)
55. *5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568-579.
56. *0101 and abrogated by low CD4 T-cell counts. Aids 19:97-99. (Pubitemid 40111026)
57. *3101 and carbamazepineinduced hypersensitivity reactions in Europeans. N Engl J Med 364:1134-1143.
58. Metushi, I. G., Cai, P., Zhu, X., Nakagawa, T., Uetrecht, J. P. (2011). A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 89:911-914.
59. Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., et al. (1975). Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 18:70-79.
60. Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., Torgeisson, U. P., Timbrell, J. A., Snodgrass, W. R., et al. (1976). Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181-192.
61. Molokhia, M., McKeigue, P. (2006). EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 7:633-638.
62. Noe, J., Kullak-Ublick, G. A., Jochum, W., Stieger, B., Kerb, R., Haberl, M., et al. (2005). Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J Hepatol 43:536-543. (Pubitemid 41111438)
63. O'Donohue, J., Oien, K. A., Donaldson, P., Underhill, J., Clare, M., Macsween, R. M., et al. (2000). Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47:717-720.
64. Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., et al. (2000). Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:256-261. (Pubitemid 30151575)
65. *3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20:1034-1041.
66. Pachkoria, K., Lucena, M. I., Crespo, E., Ruiz-Cabello, F., Lopez-Ortega, S., Fernandez, M. A., et al. (2008). Analysis of IL-10, IL-4, and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 49:107-114.
67. Pachkoria, K., Lucena, M. I., Ruiz-Cabello, F., Crespo, E., Cabello, M. R., Andrade, R. J. (2007). Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 150:808-815. (Pubitemid 46440210)
68. Possuelo, L. G., Castelan, J. A., De Brito, T. C., Ribeiro, A. W., Cafrune, P. I., Picon, P. D., et al. (2008). Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64:673-681.
69. Ritchie, M. D., Haas, D. W., Motsinger, A. A., Donahue, J. P., Erdem, H., Rafanti, S., et al. (2006). Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 43:779-782. (Pubitemid 44330745)
70. Roy, B., Chowdhury, A., Kundu, S., Santra, A., Dey, B., Chakraborty, M., et al. (2001). Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 "null" mutation. J Gastroenterol Hepatol 16:1033-1037. (Pubitemid 32947147)
71. Russmann, S., Kaye, J. A., Jick, S. S., Jick, H. (2005). Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 60:76-82. (Pubitemid 40942784)
72. Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., et al. (2006). An ofcial ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935-952. (Pubitemid 44564795)
73. Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C., et al. (2002). Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451-455. (Pubitemid 34810366)
74. Sharma, S. K., Balamurugan, A., Saha, P. K., Pandey, R. M., Mehra, N. K. (2002). Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166:916-919. (Pubitemid 35193218)
75. Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., et al. (2010). A genome-wide study identifes HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42:711-714.
76. *02:01 is a major risk factor for lapatinibinduced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29:667-673.
77. Stewart, J. D., Horvath, R., Baruffini, E., Ferrero, I., Bulst, S., Watkins, P. B., et al. (2010). Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52:1791-1796.
78. Stricker, B. H., Blok, A. P., Claas, F. H., Van Parys, G. E., Desmet, V. J. (1988). Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8:599-606.
79. Uetrecht, J. (2009). Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 29:383-392.
80. Urban, T., Shen, Y. F., Chalasani, N. P., Fontana, R. J., Rochon, J., Stolz, A., et al. (2011). A genome-wide association study identifes potential susceptibility loci for hepatotoxicity due to various drugs. Gastroenterology 140:S886-S886
81. Vuilleumier, N., Rossier, M. F., Chiappe, A., Degoumois, F., Dayer, P., Mermillod, B., et al. (2006). CYP2E1 genotype and isoniazidinduced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 62:423-429. (Pubitemid 44069498)
82. Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., et al. (2003). A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 73:435-455. (Pubitemid 36549828)
83. Xu, C. F., Reck, B. H., Goodman, V. L., Xue, Z., Huang, L., Barnes, M. R., et al. (2010). Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 54:1237-1243.
84. Yamada, S., Tang, M., Richardson, K., Halaschek-Wiener, J., Chan, M., Cook, V. J., et al. (2009). Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10:1433-1445.
85. Yee, S. B., Bourdi, M., Masson, M. J., Pohl, L. R. (2007). Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem Res Toxicol 20:734-744. (Pubitemid 46953680)
86. Yuan, J., Guo, S., Hall, D., Cammett, A. M., Jayadev, S., Distel, M., et al. (2011). Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 25:1271-1280.